The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD
Fatima Amanat, Mahima Thapa, Tinting Lei, Shaza M. Sayed Ahmed, Daniel C. Adelsberg, Juan Manuel Carreno, Shirin Strohmeier, Aaron J. Schmitz, Sarah Zafar, Julian Q Zhou, Willemijn Rijnink, Hala Alshammary, Nicholas Borcherding, Ana Gonzalez Reiche, Komal Srivastava, Emilia Mia Sordillo, Harm van Bakel, The Personalized Virology Initiative, Jackson S. Turner, Goran Bajic, View ORCID ProfileViviana Simon, Ali H. Ellebedy, Florian Krammer
doi: https://doi.org/10.1101/2021.03.07.21253098
Fatima Amanat
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
2Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Mahima Thapa
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
Tinting Lei
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
Shaza M. Sayed Ahmed
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
Daniel C. Adelsberg
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Juan Manuel Carreno
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Shirin Strohmeier
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Aaron J. Schmitz
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
Sarah Zafar
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Julian Q Zhou
4AbCellera Biologics Inc., Vancouver, BC V5Y 0A1, Canada
Willemijn Rijnink
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Hala Alshammary
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Nicholas Borcherding
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
Ana Gonzalez Reiche
5Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029
Komal Srivastava
Emilia Mia Sordillo
6Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029
Harm van Bakel
5Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029
7Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Jackson S. Turner
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
Goran Bajic
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Viviana Simon
9The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
10Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, MO 63110
Ali H. Ellebedy
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
Florian Krammer
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Data Availability
Data is available upon reasonable request from the corresponding authors.
Posted March 09, 2021.
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD
Fatima Amanat, Mahima Thapa, Tinting Lei, Shaza M. Sayed Ahmed, Daniel C. Adelsberg, Juan Manuel Carreno, Shirin Strohmeier, Aaron J. Schmitz, Sarah Zafar, Julian Q Zhou, Willemijn Rijnink, Hala Alshammary, Nicholas Borcherding, Ana Gonzalez Reiche, Komal Srivastava, Emilia Mia Sordillo, Harm van Bakel, The Personalized Virology Initiative, Jackson S. Turner, Goran Bajic, Viviana Simon, Ali H. Ellebedy, Florian Krammer
medRxiv 2021.03.07.21253098; doi: https://doi.org/10.1101/2021.03.07.21253098
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD
Fatima Amanat, Mahima Thapa, Tinting Lei, Shaza M. Sayed Ahmed, Daniel C. Adelsberg, Juan Manuel Carreno, Shirin Strohmeier, Aaron J. Schmitz, Sarah Zafar, Julian Q Zhou, Willemijn Rijnink, Hala Alshammary, Nicholas Borcherding, Ana Gonzalez Reiche, Komal Srivastava, Emilia Mia Sordillo, Harm van Bakel, The Personalized Virology Initiative, Jackson S. Turner, Goran Bajic, Viviana Simon, Ali H. Ellebedy, Florian Krammer
medRxiv 2021.03.07.21253098; doi: https://doi.org/10.1101/2021.03.07.21253098
Subject Area
Subject Areas
- Addiction Medicine (331)
- Allergy and Immunology (657)
- Anesthesia (176)
- Cardiovascular Medicine (2557)
- Dermatology (216)
- Emergency Medicine (388)
- Epidemiology (12055)
- Forensic Medicine (10)
- Gastroenterology (738)
- Genetic and Genomic Medicine (3970)
- Geriatric Medicine (373)
- Health Economics (663)
- Health Informatics (2562)
- Health Policy (991)
- Hematology (356)
- HIV/AIDS (821)
- Medical Education (393)
- Medical Ethics (106)
- Nephrology (420)
- Neurology (3732)
- Nursing (206)
- Nutrition (558)
- Oncology (1941)
- Ophthalmology (565)
- Orthopedics (233)
- Otolaryngology (299)
- Pain Medicine (246)
- Palliative Medicine (72)
- Pathology (469)
- Pediatrics (1087)
- Primary Care Research (442)
- Public and Global Health (6401)
- Radiology and Imaging (1352)
- Respiratory Medicine (854)
- Rheumatology (390)
- Sports Medicine (336)
- Surgery (430)
- Toxicology (51)
- Transplantation (184)
- Urology (161)